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Abstract. Breast cancers can express different types of
peptide receptors such as somatostatin, vasoactive in-
testinal peptide (VIP), gastrin-releasing peptide (GRP)
and NPY(Y1) receptors. The aim of this in vitro study
was to evaluate which is the most appropriate peptide
receptor or peptide receptor combination for in vivo di-
agnostic and therapeutic targeting of breast cancers.
Seventy-seven primary breast cancers and 15 breast
cancer lymph node metastases were investigated in vit-
ro for their expression of somatostatin, VPAC1, GRP
and NPY(Y1) receptors using in vitro receptor autoradi-
ography on successive tissue sections with 125I-[Tyr3]-
octreotide, 125I-VIP, 125I-[Tyr4]-bombesin and 125I-
[Leu31,Pro34]-PYY respectively. This study identified
two groups of tumours: a group of 68 tumours (88%)
with at least one receptor expressed at high density
(>2,000 dpm/mg tissue) that may provide a strong pre-
dictive value for successful in vivo targeting, and a
group of nine tumours (12%) with no receptors or only
a low density of them (<2,000 dpm/mg tissue). In the
group with high receptor density, 50 of the 68 tumours
(74%) expressed GRP receptors, 45 (66%) expressed
NPY(Y1) receptors, 25 (37%) expressed VPAC1 recep-
tors and 14 (21%) expressed somatostatin receptors.
Mean density was 9,819±530 dpm/mg tissue for GRP
receptors, 9,135±579 dpm/mg for NPY(Y1) receptors,
4,337±528 dpm/mg for somatostatin receptors and
3,437±306 dpm/mg for VPAC1 receptors. It is of note
that tumours expressing NPY(Y1) or GRP receptors, or
both, were found in 63/68 (93%) cases. Lymph node
metastases showed a similar receptor profile to the cor-
responding primary tumour. This in vitro study strongly
suggests that the combination of radiolabelled GRP and
Y1 analogues should allow targeting of breast carcino-
mas and their lymph node metastases for in vivo pep-
tide receptor scintigraphy and radiotherapy.
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Introduction
Peptide receptors expressed in human cancers can be tar-
geted in vivo with radiolabelled ligands either for diag-
nostic scintigraphy or for targeted peptide radiotherapy.
The best example is that of somatostatin and somatosta-
tin receptors [1, 2]. It has, however, been shown that the
chances of success of somatostatin receptor scintigraphy
[3, 4, 5, 6], of intraoperative tumour detection using Oct-
reoscan [7] and of somatostatin-receptor targeted radio-
therapy [2, 4, 8, 9] are greatest for those tumour types
expressing somatostatin receptors at a high density.
Breast cancers can express somatostatin receptors.
The latter are found in vitro in 50%–70% of the tumours
[10, 11, 12], sst2A being the predominant receptor sub-
type, as shown by receptor protein measurements from
either receptor binding [13] or immunohistochemistry
[14]. However, many breast cancers do not have a high
somatostatin receptor density [11, 14]. Moreover, breast
cancers are characterized by a strong somatostatin recep-
tor heterogeneity in tumour samples in vitro in at least
50% of the somatostatin receptor-positive cases, with re-
gions of high density adjacent to regions virtually devoid
of somatostatin receptors [11, 14, 15]. Successful scinti-
graphic detection of breast cancer, both primary and
metastatic, has been reported with Octreoscan; however,
the percentage of positive cases varies between 50% and
94% [12, 16, 17, 18, 19]. A well-controlled study by van
Eijck et al. [12] showed 70% somatostatin receptor posi-
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tivity in breast cancers diagnosed at mammography,
while another well-controlled study by Albérini et al.
[19] found 50% positivity. Other scintigraphic studies,
without concomitant in vitro receptor confirmation, have
reported up to a 94% incidence of positive cases [17,
18]; such figures may represent an overestimation since
non-tumoural breast tissue has also been shown to be
positive on scintigraphy in 15% of cases [2]. Despite
these encouraging data, up to now in vivo somatostatin
receptor scintigraphy has not become a recognized tool
for the routine diagnosis or radiotherapeutic somatostatin
receptor targeting of breast cancers. This is probably due
in large part to the insufficient amount and heterogene-
ous distribution of somatostatin receptors expressed by
some of these tumours.
Breast cancers can express other peptide receptors
than those for somatostatin. VIP receptors of the VPAC1
subtype have been shown in vitro to be expressed in the
majority of breast cancers and metastases [20, 21, 22].
Gastrin-releasing peptide (GPR) receptors have been
found in high density in more than two-thirds of these
cancers with in vitro methods [23, 24]. Recently,
NPY(Y1) receptors were also shown to be abundantly
expressed in vitro in breast cancers [25]. Individually,
however, none of these receptors is expressed in 100%
of cases in sufficiently high density and with sufficient
homogeneity to permit tumour identification and therapy
of all cancer sites in all patients. Although it should theo-
retically be possible to combine several of the above-
mentioned peptides for optimal in vivo targeting of pri-
maries and metastases, there are presently no in vitro
studies indicating which peptides would be worth com-
bining in such a cocktail.
The aim of this study was to quantitatively compare
the tissue distribution and the protein expression of four
peptide receptors, namely somatostatin, VIP, GRP and
NPY(Y1) receptors, in successive sections of breast car-
cinomas, using receptor autoradiography. Our goal was
to identify which peptide receptor or receptor combina-
tion was expressed most frequently and in highest densi-
ty in breast cancers, in order to recommend to nuclear
physicians the optimal peptide combination for detection
and therapeutic targeting of primary tumours and metas-
tases.
Materials and methods
Breast cancer samples from 77 patients were included in this
study. They consisted of 77 primary tumours as well as 15 lymph
node metastases from four of these patients. The diagnosis was re-
viewed and formulated by use of cryostat sections, according to
the WHO guidelines stated by Tavassoli [26]. Of 77 patients, 58
(75%) were found to have an invasive ductal carcinoma. Histolog-
ical evaluation identified a great majority of cases (n=45) with in-
termediate grade (G2), while nine cases had a low grade (G1) and
four cases a high grade (G3), according to a modified Bloom-
Richardson grading method [26]. There were nine invasive lobular
carcinomas and two ductal carcinomas in situ, as well as three mu-
cinous, two medullary, two apocrine and one tubular carcinoma.
Using in vitro receptor autoradiography in successive sections of
each tumour case, we compared the expression of somatostatin re-
ceptors (octreotide binding), VIP receptors, GRP receptors and
NPY receptors of the Y1 subtype.
Knowing from previous studies that many of these receptors
are expressed heterogeneously within the breast cancers, care was
taken to evaluate the receptor status on large tumour samples (one
sample per tumour) in order to obtain more representative results.
The mean surface area of the 77 investigated tumour sections was
138±66 mm2. Somatostatin receptor autoradiography was per-
formed as demonstrated previously using 125I-[Tyr3]-octreotide
(2,000 Ci/mmol, Anawa) as tracer, in order to identify the binding
sites recognized by octreotide and Octreoscan [11, 27]. VIP recep-
tor autoradiography was performed with 125I-VIP (2,000 Ci/mmol,
Anawa) as radioligand [21]. For every single tumour, the VPAC1
or VPAC2 receptor subtype expression was assessed using the
VPAC1-selective analogue [K15,R16,L27]VIP(1–7)/GRF(8–27) and
the VPAC2-selective analogue Ro25-1553 for selective displace-
ment, as reported previously [21]. For GRP receptors, 125I-[Tyr4]-
bombesin was used as ligand [23]. For NPY(Y1) receptor autora-
diography, 125I-[Leu31,Pro34]-PYY was used as a selective Y1 li-
gand [25].
In all cases, the autoradiographs were quantified using a com-
puter-assisted image processing system, as described previously
[27]. Tissue standards for iodinated compounds (Amersham,
Aylesbury, UK) were used for this purpose. A tissue was defined
as receptor-positive when the absorbance measured in the total
binding section was at least twice that of the non-specific binding
section. In addition, by setting a cut-off point for receptor density
at 2,000 dpm/mg tissue, we arbitrarily distinguished two groups of
tumours: those with high receptor density (>2,000 dpm/mg tissue),
that is likely to represent a clinically relevant positivity, in particu-
lar for radiotherapy, and those with low receptor density
(<2,000 dpm/mg tissue) or no receptors at all. This cut-off point
was based on our previous experience with somatostatin receptors
[27, 28, 29].
Results
Table 1 shows the various primary breast tumour carcino-
mas grouped according to their receptor profile. The very
strict selection of strongly receptor-positive tumours, i.e.
those with a receptor density of >2,000 dpm/mg tissue, as
mentioned above, should permit more conclusive assess-
ments to be made regarding potential clinical implica-
tions for the corresponding peptide receptor group. To
provide full information, Table 1 reports not only the re-
ceptor density values for high-density receptor speci-
mens but also those for specimens with a low receptor
density.
All 77 primary tumour samples showed expression of
at least one of the four peptide receptors. However, nine
cases did not express any of the four receptors in high
density. Thus, as many as 68/77 (88%) cancers had at
least one peptide receptor expressed in high density (Ta-
ble 1). In these 68 cases, the receptor type most frequent-
ly expressed was the GRP receptor (50/68 cases, 74%),
followed by the NPY(Y1) receptor (45/68, 66%). A high
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density of VIP receptors was found much less frequently
(25/68, 37%), although VIP receptors (high and low 
density) were found in the majority of the 68 tumours
tested (63/68, 93%). In all cases, the VIP receptors were
of the VPAC1 type, with a high affinity for
[K15,R16,L27]VIP(1–7)/GRP(8–27) but no affinity for
Ro25-1553. A high density of somatostatin receptors
identified with 125I-[Tyr3]-octreotide was found in a mi-
nority of cases (14/68, 21%) whereas the total number of
tumours with somatostatin receptors (high or low densi-
ty) in this series amounted to 51/68 (75%). Interestingly,
as many as 41 (60%) of the 68 tumours co-expressed two
to four receptor types. A further important observation
was that the number of tumours expressing a high densi-
ty of GRP or NPY(Y1) receptors, or both, was as high as
63/68 (93%) in the group of high receptor density speci-
mens or 63/77 (82%) in the whole group of tested prima-
ry breast cancers. The other interesting result is related
to the mean values of receptor density for each receptor
type: highest mean density values, 9,819±530 dpm/mg
tissue, were found for the 50 GRP receptor-positive
cases, while the 45 NPY(Y1) receptor-positive cases
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Table 1. Receptor profiles of the 68 primary breast cancers with at
least one receptor expressed at high density (>2,000 dpm/mg tis-
sue). Receptor densities are shown within parentheses for those
cases with low receptor densities (<2,000 dpm/mg tissue). Recep-
tor density values are expressed as mean±SEM (n≥3).
Receptor profile No. of tumours Somatostatin-R VIP-R GRP-R NPY(Y1)-R
4 receptors
SS-R
n=4
+ + + +
VIP-R 5,616±1,023 4,004±750 8,383±2,644 11,258±546
GRP-R
NPY(Y1)-R
3 receptors
SS-R + + +
VIP-R n=1 3,390 6,287 (183) 12,452
NPY(Y1)-R
SS-R + + +
VIP-R n=2 2,391; 5,674 2,237; 2,132 12,014; 13,323 (161, n=1)
GRP-R
SS-R + + +
GRP-R n=5 4,308±967 (984±113, n=5) 12,274±846 10,325±985
NPY(Y1)-R
VIP-R + + +
GRP-R n=9 (1,002±219, n=8) 3,413±462 7,564±1,151 9,256±1,434
NPY(Y1)-R
2 receptors
GRP-R
n=14 (1,077±208, n=11) (1,174±116, n=14) + +NPY(Y1)-R 11,053±731 9,751±1,156
VIP-R
n=4 (126; 32,5, n=2) + (1,411, n=1) +NPY(Y1)-R 3,736±996 5,531±1,542
SS-R
n=2 + (1,380, n=1) + (133; 1,494)GRP-R 2,062; 3,194 11,131; 8,263
1 receptor
GRP-R
n=14 (505±174, n=7) (645±155, n=12) + (530±223, n=8)9,179±1,209
NPY(Y1)-R n=8 (309±73, n=4) (865±158, n=6) (679±408, n=4) +
7,503±1,375
VIP-R
n=5 (314±58, n=5) + (149±32, n=3) (345±184, n=3)2,719±489
Total
n=68 14/68 25/68 50/68 45/684,337±528 3,437±306 9,819±530 9,135±579
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Fig. 1A–E. Breast cancer with four peptide receptors expressed
homogeneously in the whole tumour sample. A Haematoxylin-eo-
sin stained section. Bar =1 mm. B Autoradiograph showing total
binding of 125I-[Tyr3]-octreotide. C Autoradiograph showing total
binding of 125I-[Tyr4]-bombesin. D Autoradiograph showing total
binding of 125I-[Leu31,Pro34]-PYY. E Autoradiograph showing to-
tal binding of 125I-VIP. All four receptors are expressed in high
density in the whole tumour sample. In all four cases, non-specific
binding was found to be negligible
Fig. 2A–E. The most frequently found receptor profile in breast
carcinomas: high density of GRP receptors and NPY(Y1). A Hae-
matoxylin-eosin stained section. Bar =1 mm. B Autoradiograph
showing total binding of 125I-[Tyr3]-octreotide. C Autoradiograph
showing total binding of 125I-[Tyr4]-bombesin. D Autoradiograph
showing total binding of 125I-[Leu31,Pro34]-PYY. E Autoradio-
graph showing total binding of 125I-VIP. NPY(Y1) and GRP recep-
tors are expressed in high density in the whole tumour. Somatosta-
tin receptors and VIP are expressed in low density only
Fig. 3A–E. Breast carcinoma with four peptide receptors ex-
pressed in a distinct topography. A Haematoxylin-eosin stained
section. Bar =1 mm. B Autoradiograph showing total binding of
125I-[Tyr3]-octreotide. C Autoradiograph showing total binding of
125I-[Tyr4]-bombesin. D Autoradiograph showing total binding of
125I-[Leu31,Pro34]-PYY. E Autoradiograph showing total binding
of 125I-VIP. Somatostatin and GRP receptors are heterogeneously
and complementarily expressed while NPY(Y1) and VIP receptors
are homogeneously expressed
tin and GRP receptors, while NPY(Y1) and VPAC1 re-
ceptors were expressed in the whole tumour sample.
The 9/77 tumours having only low receptor density
had the following receptor profile: seven cases had so-
matostatin receptors (mean density: 668±280 dpm/mg
tissue), all nine had VPAC1 receptors (707±101 dpm/mg
tissue); five had GRP receptors (690±267 dpm/mg tis-
sue) and eight had NPY(Y1) receptors (566±207 dpm/mg
tissue).
Table 2 shows the receptor profile in four breast can-
cer patients and compares the respective receptor density
in their primary tumours and in the various axillary
lymph node metastases. Although there are marked vari-
ations in density, the peptide receptor profile found in
the primary tumour is the same as in nodal metastases in
three of the four patients: Case no. 1 has an NPY(Y1) re-
ceptor profile both in the primary tumour and in the me-
tastasis. Case no. 2 expresses somatostatin, GRP and
NPY(Y1) receptors in the primary tumour and in the two
metastases. Case no. 3 has a GRP and NPY(Y1) receptor
profile, with lower levels of VPAC1 receptors, in the pri-
mary tumour and the majority of the metastases. Only
case no. 4 has an inconsistent profile differing in the pri-
mary tumour and in the metastases. An example of a
comparable receptor profile in a primary tumour and its
metastasis is shown in Fig. 4. 
Discussion
This in vitro receptor autoradiography study shows that
among several peptide receptor candidates expressed in
breast carcinomas, some may be more suitable than oth-
ers for potential in vivo clinical use in nuclear medicine,
based on their incidence, density and tumour distribution
in vitro. Among the four peptide receptors tested, this
study shows that GRP and NPY(Y1) receptors are those
peptide receptors most frequently expressed in high den-
sity in resectable primary breast cancers, as they are
found, alone or together, in more than 82% of these can-
cers. Lymph node metastases, as far as could be evaluat-
ed in this study, appear to have a similar peptide receptor
profile to their corresponding primary tumours. We do
not, however, know the receptor profile of distant metas-
tases (bone metastases) in patients with advanced, non-
resectable metastatic breast cancer.
The present in vitro determination of four different
peptide receptors in human breast cancers is a predictive
study that could lead to a novel approach to improve and
optimize breast cancer targeting in vivo with radiopep-
tides. According to the present in vitro data, the simulta-
neous application of radiolabelled GRP (or bombesin)
and NPY(Y1) receptor-selective analogues in vivo
should permit scintigraphic visualisation of a large num-
ber of breast cancers. The present study was primarily
based on tumours from patients with resectable primary
breast cancers, and it is this group among the breast can-
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showed a mean density of 9,135±579 dpm/mg tissue.
Much lower densities were found in the 14 somatostatin
receptor-positive cases (4,337±528 dpm/mg tissue) 
and in the 25 VPAC1 receptor-positive cases (3,437±
306 dpm/mg tissue). A typical example of a tumour with
all four receptors expressed in high density is seen in
Fig. 1. Figure 2 shows the receptor profile found most
frequently in this breast cancer series, namely a high
density of GRP receptors combined with NPY(Y1) re-
ceptors. No correlation was found between the tumour
type or tumour grade and the peptide receptor status. In
particular, tumours with grade 1 or grade 3 were not
found to have a receptor status (profile, density) distinct
from those with grade 2. 
Topographical heterogeneity of somatostatin recep-
tors was found in 9/25 cases (36%) having a high recep-
tor density, of VPAC1 receptors in 2/25 cases (8%), of
GRP receptors in 14/50 cases (28%) and of NPY(Y1) in
12/45 cases (27%). Importantly, in all but two cases with
heterogeneous receptor distribution, the area with low or
no receptor content for a given receptor was positive for
at least one of the other tested receptors. Figure 3 shows
an example of heterogeneous distribution for somatosta-
Table 2. Examples comparing the peptide receptor profile in indi-
vidual primary tumours (PT) with their lymph node metastases
(LN) in four cases of breast carcinoma
Case Somatostatin-R VIP-R GRP-R NPY(Y1)-R
No. 1
PT 0 914 0 14,766
LN 156 4,293 364 12,621
No. 2
PT 3,288 786 14,741 10,723
LN1 4,557 1,475 16,231 13,266
LN2 4,144 2,600 12,824 12,510
No. 3
PT 0 1,428 13,849 10,267
LN1 0 2,360 15,697 10,724
LN2 0 2,329 1,121 10,687
LN3 0 1,058 1,628 5,823
LN4 105 2,730 2,588 11,215
LN5 122 942 7,150 10,158
LN6 85 1,119 775 11,652
LN7 246 1,038 9,693 6,037
LN8 131 1,231 13,911 10,608
LN9 0 1,225 1,217 9,207
No. 4
PT 0 623 12,622 17,663
LN1 967 3,739 0 15,464
LN2 1,316 4,975 343 14,074
LN3 3,697 1,193 796 13,746
Numbers represent receptor density values expressed in dpm/mg
tissues
860
European Journal of Nuclear Medicine Vol. 29, No. 7, July 2002
cer population that should represent the first selection for
in vivo scanning, given the high chance of tumour detec-
tion. However, once the in vivo proof of principle has
been obtained in this group of patients, it will be essen-
tial also to scan patients with advanced metastatic breast
cancers, including recurrent and/or hormone-resistant
breast cancers, to gain in vivo information on the recep-
tor status in this category of patients, not available from
the present in vitro study. In such cases, GRP/NPY scin-
tigraphy may represent a tool to assess whether the pep-
tide receptor expression of the primary tumour, lymph
node metastases and bone metastases is comparable in a
given breast cancer patient and, in this regard, may help
clarify the extent to which breast cancer is a systemic
disease [30, 31]. Furthermore, it is worth considering
that the presence of a high receptor density may permit
detection of lymph node metastases harbouring only
very small areas of tumour cells. Would, for instance,
sentinel lymph nodes [32] be adequately visualized
through in vivo targeting of these two receptors?
Based on the strict selection of tumours with a high
density of receptors, the receptor density in more than
82% of these tumours should be sufficiently high also to
permit targeted peptide radiotherapy with the same ana-
logues. Indeed, the density of GRP and/or NPY(Y1) re-
ceptors expressed in these breast cancers equals or even
exceeds the number of somatostatin receptors usually ex-
pressed by neuroendocrine tumours [27, 28]. The latter
have been shown to be the most suitable candidates for
somatostatin radiotherapy [8, 9, 33]. As is the case for
somatostatin receptor radiotherapy [2], an inclusion cri-
terion for GRP/NPY receptor radiotherapy should be
strongly GRP/NPY receptor-positive scintigraphy of the
tumour in that patient.
Fig. 4A–K. Receptor profile in
a primary tumour (PT, left) and
its lymph node metastasis 
(Meta, right). A, F Haematoxy-
lin-eosin stained sections. 
Bars =1 mm. B, G Autoradio-
graphs showing total binding 
of 125I-[Tyr3]-octreotide. 
C, H Autoradiographs showing
total binding of 125I-[Tyr4]-
bombesin. D, I Autoradio-
graphs showing total binding 
of 125I-[Leu31,Pro34]-PYY. 
E, K Autoradiographs showing
total binding of 125I-VIP. While
somatostatin receptors are ab-
sent, the three others are
strongly expressed in the pri-
mary tumour and in its metasta-
sis, with GRP receptors found
in the highest density. Interest-
ingly, NPY(Y1) receptors are
found heterogeneously in the
primary tumour, while the en-
tire lymph node metastasis is
NPY(Y1) receptor positive
Radioactivity background in the thorax and breast
should not be problematic, as neither GRP nor NPY(Y1)
receptors are expressed in the lung. NPY(Y2) rather than
NPY(Y1) receptors are preferentially expressed in the
normal breast [25]; GRP receptors are, however, fre-
quently found in the normal breast [23]. The presence of
these GRP receptors in normal breast does not appear to
seriously hamper the detection of primary breast tu-
mours, probably due to the much lower cellularity of the
glandular tissue per organ volume compared with tumour
tissue. Indeed, GRP receptor scintigraphy was recently
initiated with a technetium-99m labelled bombesin ana-
logue and shown to successfully visualize breast cancers
[34], even though in normal volunteers the normal breast
gave a weak positive signal [35].
It is questionable whether it would be worth applying
three or four radiopeptides concomitantly, namely oct-
reotide and/or VIP in combination with the GRP and
NPY(Y1) analogues. On the one hand, this would cer-
tainly allow detection of a higher proportion of breast
cancers, including perhaps even the small percentage
(12%) of tumours with low receptor densities only. A
significant drawback, on the other hand, would be the in-
creased radioactivity background of the three to four
concomitantly applied radioligands. While somatostatin
receptor scintigraphy does not show a strong background
over the thoracic area owing to a lack of sst2 receptors in
normal breasts and lungs, VIP receptor scintigraphy is
characterized by a strong lung uptake based on VPAC1
receptors in this tissue [21]. Masking by these lung
VPAC1 receptors may prevent the detection of a positive
breast cancer in this area, while the VPAC1 receptors ex-
pressed in the normal breast will probably play only a
minor role in this respect [21]. Furthermore, adding so-
matostatin to GRP and NPY(Y1) analogues for scintigra-
phy may not be a sufficiently great advantage in terms of
increased tumour signal, given the generally lower inci-
dence and density of somatostatin receptors compared
with GRP and NPY(Y1) receptors in breast cancers.
Based on the above arguments, the combination of GRP
and NPY(Y1) appears preferable.
Prerequisites for a clinical trial are the development
of NPY(Y1) radiopharmaceuticals and the optimization
of the GRP radiopharmaceuticals presently available.
99mTc-labelled NPY analogues selective for Y2 have re-
cently been synthesized [36]. Moreover, novel and spe-
cific Y1 ligands have recently been reported [37] that
need to be linked to chelators for radioimaging. While
several radioligands specific for GRP receptors have
been synthesized [38, 39, 40], only the 99mTc-labelled
bombesin analogue RP527 has been used to target hu-
man tumours up to now [34, 35]. The present study may
therefore trigger and motivate the initiation of new pre-
clinical and clinical studies in these directions.
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